Limitations and uncertainty around telehealth reimbursement have always been an impediment to adoption. During the COVID-19 emergency, that burden was eased somewhat, but now the new normal is starting to take shape. What barriers still remain to telehealth reimbursement, and how might they be overcome?  To answer that question, host Jonah Comstock and Healthcare Finance News Managing Editor Susan Morse welcome McKinsey & Company Partners Oleg Bestsennyy and Gunjan Khanna.

This episode is brought to you by BlueJeans.

Talking points:

• COVID-19 reimbursement changes and which of them will stick around
• Adoption lessons learned and how they’ll influence reimbursement policy
• Holistic tele-care and care beyond the video visit
• Influence of new entrants and innovation on the space
• Is fee-for-service reimbursement an innovation blocker?
• Reimbursement for different telehealth modalities
• Time to lead rather than follow for private payers?
• The still-unresolved question of induced utilization
• The rise of value-based care and hybrid care models
• Telehealth reimbursement and health equity
• How are patients feeling about telehealth now?
• Final thoughts: the future of telehealth reimbursement

More about this episode:

Report shows 'vast improvement' in state telehealth reimbursement policies

COVID-19 may permanently alter the telehealth landscape, from reimbursement to utilization

Telehealth reimbursement parity spurs insurer concerns of overutilization

CMS will reimburse for 11 new telehealth services during the public health emergency

Telehealth: A quarter-trillion-dollar post-COVID-19 reality? (McKinsey)

COVID-19 Consumer Healthcare Insights: What 2021 may hold (McKinsey)

How COVID-19 has changed the way US consumers think about healthcare (McKinsey)